Mazdutide vs Efinopegdutide
Head-to-head comparison of Mazdutide (IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist) and Efinopegdutide (Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Mazdutide | Efinopegdutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist | Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | ~5,000 Da | N/A |
| Half-Life | 5-7 days | Approximately 1 week |
| Amino Acids | 37 | N/A |
| Typical Dose | 1-6 mg weekly in obesity trials | Trial-dependent; weekly SC dosing |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 28 | 14 |
| Research Status | Clinical | Clinical |
Mazdutide Benefits
- ✓clinically meaningful weight loss
- ✓better glycemic control
- ✓reduced waist circumference
- ✓improved lipid profile
Efinopegdutide Benefits
- ✓reduced body weight
- ✓improved insulin sensitivity
- ✓reduced liver fat
- ✓greater satiety
Mazdutide Dosing
Once-weekly SC titration|Dose escalation every 4 weeks|Use with lifestyle modification
Efinopegdutide Dosing
once-weekly subcutaneous injection|dose escalation during lead-in|maintenance dosing in trials
Mazdutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠constipation
Efinopegdutide Side Effects
- ⚠nausea
- ⚠decreased appetite
- ⚠fatigue
Research Overview
Mazdutide
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Efinopegdutide
Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.